The primary endpoint was significantly reduced by prasugrel in the overall NSTE-ACS population ( hazard ratio ( HR ) 0.82 , 95 % confidence interval ( CI ) 0.73-0 .93 , p = 0.002 ) as well as in unstable angina ( UA ) and in non-ST elevation myocardial infarction ( NSTEMI ) patient subgroups ( interaction p value = 0.39 ) .